Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: Implications for fluoropyrimidine radiosensitization

Cancer Research

Volumn 60, Issue 1, 2000, Pages 92-100

  Hwang, Hwa Shin ^a   Davis, Thomas W ^a   Houghton, Janet A ^b   Kinsella, Timothy J ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEOTIDE; DNA FRAGMENT; FLUOROPYRIMIDINE; LEUCINE; MIMOSINE; THYMIDYLATE SYNTHASE;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL SURVIVAL; CELL SYNCHRONIZATION; DNA DAMAGE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; TUMOR CELL CULTURE;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; CELL SURVIVAL; DEOXYRIBONUCLEOSIDES; DNA DAMAGE; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; HUMANS; NEOPLASM PROTEINS; PYRIMIDINES; RADIATION TOLERANCE; S PHASE; THYMIDYLATE SYNTHASE; THYMINE NUCLEOTIDES;

EID: 0033970910     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Kinsella, T. J. An approach to the radiosensitization of human tumors. Cancer J. Sci. Am., 2: 184-193, 1996.
2. McGinn, C. J., Shewach, D. S., and Lawrence, T. S. Radiosensitizing nucleosides. J. Natl. Cancer Inst., 88: 1193-1203, 1996.
3. Heidelberger, C., Danenberg, P. V., and Moran, R. G. Fluorinated pyrimidines and their nucleosides. Adv. Enzymol. Relat. Areas Mol. Biol., 54: 58-119, 1983.
4. Grem, J. L. Mechanisms of action and modulation of fluorouracil. Semin. Radiat. Oncol., 7: 249-259, 1997.
5. Yoshioka, A., Tanaka, S., Hiraoka, O., Koyama, Y., Hirota, Y., Ayusawa, D., Seno, T., Garrett, C., and Wataya, Y. Deoxyribonucleoside triphosphate imbalance: 5-fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J. Biol. Chem., 262: 8235-8241, 1987.
6. Pizzorno, G., Sun, Z., and Handschumacher, R. E. Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem. Pharmacol., 49: 553-557, 1995.
7. Inaba, M., and Mitsuhashi, J. Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. Oncol. Res., 6: 303-309, 1994.
8. Hwang, H-S., Ohtani, M., Nakazawa, T., Igaki, T., Masui, O., Kankawa, S., Nakayama, C., Yoshida, S., Yoshioka, A., and Wataya, Y. Molecular mechanism of 5-fluoro-2'-deoxyuridine-induced dNTP imbalance death. Nucleosides Nucleotides, 14: 2089-2097, 1995.
9. Dusenbury, C. E., Davis, M. A., Lawrence, T. S., and Maybaum, J. Induction of megabase DNA fragments by 5-fluorodeoxyuridine in human colorectal tumor (HT29) cells. Mol. Pharmacol., 39: 285-289, 1991.
10. Heidelberger, C., Griesbach, L., Montag, B. J., Mooren, D., Cruz, D., Schnitzer, R. J., and Grunberg, E. Studies on fluorinated pyrimidines II. Effects on transplanted tumors. Cancer Res., 18: 305-317, 1958.
11. Moertel, C. G., Childs, D. S., Jr., Reitemeier, R. J., Colby, M. Y., Jr., and Holbrook, M. A. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet, 2: 865-867, 1969.
12. Thomas, P. R., and Lindblad, A. S. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother. Oncol., 13: 245-252, 1988.
13. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer (Phila.). 59: 2006-2010, 1987.
14. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J. Clin. Oncol., 10: 549-557, 1992.
15. Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., Twito, D. I., Morton R. F., Veeder, M. H., Witzig, T. E., Cha, S., and Vidyarthi, S. C. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med., 324: 709-715, 1991.
16. O'Tonnell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., and Rich, T. A. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med., 331: 502-507, 1994.
17. Herskovic, A., Martz, K., al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V., Cooper, J., Byhardt, R., Davis, L., and Emami, B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med., 24: 1593-1598, 1992.
18. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA, 264: 1444-1450, 1990.
19. Byfield, J. E., Calabro-Jones, P., Klisak, I., and Kulhanian, F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int. J. Radiat. Oncol. Biol. Phys., 8: 1923-1933, 1982.
20. Byfield, J. E. Useful interaction between 5-fluorouracil and radiation in man: 5-fluorouracil as a radiosensitizer. In: B. T. Hill and A. S. Bellamy (eds.), Antitumor Drug-Radiation Interactions, pp. 87-105. Boca Raton, FL: CRC Press Inc., 1990.
21. Weinberg, M. J., Lapointe, T. A., and Rauth, A. M. Growth delay in a murine squamous cell tumor after local radiation and concurrent infusional 5-fluorouracil treatment. Int. J. Radiat. Oncol. Biol. Phys., 12: 1449-1452, 1986.
22. Weinberg, M. J., and Rauth, A. M. 5-Fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 13: 1691-1699, 1987.
23. Miller, E. M., and Kinsella, T. J. Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res., 52: 1687-1694, 1992.
24. Lawrence, T. S., Davis, M. A., and Maybaum, J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int. J. Radiat. Oncol. Biol. Phys., 29: 519-523, 1994.
25. McGinn, C. J., Miller, E. M., Lindstrom, M. J., Kunugi, K. A., Johnston, P. G., and Kinsella, T. J. The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. Int. J. Radiat. Oncol. Biol. Phys., 30: 851-859, 1994.
26. Davis, M. A., Tang, H. Y., Maybaum, J., and Lawrence, T. S. Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int. J. Radiat. Biol., 67: 509-517, 1995.
27. Lawrence, T. S., Davis, M. A., Chang, E. Y., Canman, C. E., Maybaum, J., and Radany, E. H. Lack of dependence of 5-fluorodeoxyuridine-mediated radiosensitization on cytotoxicity. Radiat. Res., 143: 281-285, 1995.
28. Heimburger, D. K., Shewach, D. S., and Lawrence, T. S. The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells. Int. J. Radiat. Oncol. Biol. Phys., 21: 983-987, 1991.
29. Lawrence, T. S., Davis, M. A., and Loney, T. L. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res., 56: 3203-3206, 1996.
30. Naida, J. D., Davis, M. A., and Lawrence, T. S. The effect of activation of wild-type p53 function on fluoropyrimidine-mediated radiosensitization. Int. J. Radiat. Oncol. Biol. Phys., 41: 675-680, 1998.
31. Houghton, P. J., Germain, G. S., Hazelton, B. J., Pennington, J. W., and Houghton, J. A. Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency. Proc. Natl. Acad. Sci. USA, 86: 1377-1381, 1989.
32. Houghton, J. A., Harwood, F. G., and Houghton, P. J. Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res., 54: 4967-4973, 1994.
33. Houghton, J. A., Tillman, D. M., and Harwood, F. G. Ratio of 2'-deoxyadenosine-5'-triphosphate/thymidine-5'-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin. Cancer Res., 1: 723-730, 1995.
34. Harwood, F. G., Frazier, M. W., Krajewski, S., Reed, J. C., and Houghton, J. A. Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells. Oncogene, 12: 2057-2067. 1996.
35. Houghton, J. A., Harwood, F. G., and Tillman, D. M. Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc. Natl. Acad. Sci. USA, 94: 8144-8149, 1997.
36. Hoffman, B. D., Hanauske-Abel, H. M., Flint, A., and Lalande, M. A new class of reversible cell cycle inhibitors. Cytometry, 12: 26-32, 1991.
37. Mosca, P. J., Dijkwel, P. A., and Hamlin, J. L. The plant amino acid mimosine may inhibit initiation at origins of replication in Chinese hamster cells. Mol. Cell. Biol., 12: 4375-4383, 1992.
38. Tanaka, K., Yoshioka, A., Tanaka, S., and Wataya, Y. An improved method for the quantitative determination of deoxyribonucleoside triphosphates in cell extracts. Anal. Biochem., 139: 35-41, 1984.
39. Darzynkiewicz, Z., Li, X., and Gong, J. Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol., 41: 15-38, 1994.
40. Schutte, B., Reynders, M. M., van Assche, C. L., Hupperets, P. S., Bosman, F. T., and Blijham, G. H. An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry. Cytometry, 8: 372-376, 1987.
41. Lindstrom, M. J., Kunugi, K. A., and Kinsella, T. J. Global comparison of radiation and chemotherapy dose-response curves with a test for interaction. Radiat. Res., 135: 269-277, 1993.
42. Cohen, S. S., and Barner, H. D. Studies on unbalanced growth in Escherichia coli. Proc. Natl. Acad. Sci. USA, 40: 885-893, 1954.
43. Ayusawa, D., Koyama, H., Iwata, K., and Seno, T. Single-step selection of mouse FM3A cell mutant defective in thymidylate synthetase. Somatic Cell Genet., 6: 261-270, 1980.
44. Hori, T., Ayusawa, D., Shimizu, K., Koyama, H., and Seno, T. Chromosome breakage induced by thymidylate stress in thymidylate synthase-negative mutants of mouse FM3A cells. Cancer Res., 44: 703-709, 1984.
45. Reichard, P. Interactions between deoxyribonucleotide and DNA synthesis. Annu. Rev. Biochem., 57: 349-374, 1988.
46. Haynes, R. H. Molecular mechanisms in genetic stability and change: the role of deoxyribonucleotide pool balance. Basic Life Sci., 31: 1-23, 1985.
47. Gilbert, D. M., Neilson, A., Miyazawa, H., DePamphilis, M. L., and Burhans, W. C. Mimosine arrests DNA synthesis at replication forks by inhibiting deoxyribonucleotide metabolism. J. Biol. Chem., 270: 9597-9606, 1995.
48. Hughes, T. A., and Cook, P. R. Mimosine arrests the cell cycle after cells enter S-phase. Exp. Cell Res., 222: 275-280, 1996.
49. Kalejta, R. F., and Hamlin, J. L. The dual effect of mimosine on DNA replication. Exp. Cell Res., 231: 173-183, 1997.
50. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
51. McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
52. Youm, G. L., Haas-Kogan, D. A., Vidair, C. A., Haas, M., Dewey, W. C., and Israel, M. A. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res., 56: 500-506, 1996.
53. Siles, E., Villalobos, M., Valenzuela, M. T., Nunez, M. I., Gordon, A., McMillan, T. J., Pedraza, V., and Ruiz de Almodovar, J. M. Relationship between p53 status and radiosensitivity in human tumour cell lines. Br. J. Cancer, 73: 581-588, 1996.
54. Quiet, C. A., Weichselbaum, R. R., and Grdina, D. J. Variation in radiation sensitivity during the cell cycle of two human squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys., 20: 733-738, 1991.
55. 1-phase checkpoint. Radiat. Res., 145: 289-298, 1996.
56. DeWeese, T. L., Walsh, J. C., Dillehay, L. E., Kessis, T. D., Hedrick, L., Cho, K. R., and Nelson, W. G. Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. Int. J. Radiat. Oncol. Biol. Phys., 37: 145-154, 1997.
57. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821-1828, 1994.
58. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
59. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
60. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993.
61. McDonald, E. R., 3rd, Wu, G. S., Waldman, T., and El-Deiry, W. S. Repair defect in p21 WAFI/C1P1-/- human cancer cells. Cancer Res., 56: 2250-2255, 1996.
62. Wadler, S., Horowitz, R., Zhang, H. Y., and Schwartz, E. L. Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells. Biochem. Pharmacol., 55: 1353-1360, 1998.